Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC9A1 | P19634 | 1/20 | 0.34 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.34 |
| ▸ | BRD2 | P25440 | 10/20 | 0.32 |
| ▸ | BRD3 | Q15059 | 10/20 | 0.32 |
| ▸ | CREBBP | Q92793 | 10/20 | 0.32 |
| ▸ | BRD4 | O60885 | 9/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.31 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.31 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31220956 | 0.75 | — | — | |
| SCHEMBL24401829 | 0.71 | SMN1; SMN2 (0.42) | SMN1; SMN2 | |
| SCHEMBL24401874 | 0.71 | KDM4E (0.39) | KDM4ELMNAMAPTSMN1; SMN2NPC1 | |
| SCHEMBL1512514 | 0.69 | CDK1 (0.40) | KDM4ELMNATSHRMEN1NPC1 | |
| SCHEMBL22322755 | 0.68 | KEAP1 (0.36) | SLC9A1KEAP1KDM4EHCAR3CYP19A1 | |
| SCHEMBL31288086 | 0.68 | — | — | |
| SCHEMBL24403120 | 0.68 | — | — | |
| SCHEMBL16244304 | 0.68 | BRD4 (0.42) | BRD2BRD3CREBBPBRD4LMNA | |
| SCHEMBL31288102 | 0.68 | — | — | |
| SCHEMBL23116058 | 0.68 | ADORA2A (0.42) | LMNAMAPTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3166945-B1 | NOVEL TRIAZOLOPYRIMIDINONE OR TRIAZOLOPYRIDINONE DERIVATIVES, AND USE THEREOF | ST PHARM CO LTD (KR) | 2019-10-09 | — | — | EP | disclosed |
| EP-3166945-B1 | NOVEL TRIAZOLOPYRIMIDINONE OR TRIAZOLOPYRIDINONE DERIVATIVES, AND USE THEREOF | ST PHARM CO LTD (KR) | 2019-10-09 | — | — | EP | disclosed |
| US-9914737-B2 | Triazolopyrimidinone or triazolopyridinone derivatives, and use thereof | ST PHARM CO., LTD. (KR) | 2018-03-13 | — | — | US | disclosed |
| US-9914737-B2 | Triazolopyrimidinone or triazolopyridinone derivatives, and use thereof | ST PHARM CO., LTD. (KR) | 2018-03-13 | — | — | US | disclosed |
| US-9914737-B2 | Triazolopyrimidinone or triazolopyridinone derivatives, and use thereof | ST PHARM CO., LTD. (KR) | 2018-03-13 | — | — | US | disclosed |
| US-20170145016-A1 | NOVEL TRIAZOLOPYRIMIDINONE OR TRIAZOLOPYRIDINONE DERIVATIVES, AND USE THEREOF | ST PHARM CO., LTD. (KR) | 2017-05-25 | — | — | US | disclosed |
| US-20170145016-A1 | NOVEL TRIAZOLOPYRIMIDINONE OR TRIAZOLOPYRIDINONE DERIVATIVES, AND USE THEREOF | ST PHARM CO., LTD. (KR) | 2017-05-25 | — | — | US | disclosed |
| US-20170145016-A1 | NOVEL TRIAZOLOPYRIMIDINONE OR TRIAZOLOPYRIDINONE DERIVATIVES, AND USE THEREOF | ST PHARM CO., LTD. (KR) | 2017-05-25 | — | — | US | disclosed |
| EP-3166945-A2 | NOVEL TRIAZOLOPYRIMIDINONE OR TRIAZOLOPYRIDINONE DERIVATIVES, AND USE THEREOF | ST Pharm Co. Ltd. (KR) | 2017-05-17 | — | — | EP | disclosed |
| WO-2016006974-A2 | NOVEL TRIAZOLOPYRIMIDINONE OR TRIAZOLOPYRIDINONE DERIVATIVES, AND USE THEREOF | ST PHARM CO., LTD. (KR) | 2016-01-14 | — | — | WO | disclosed |
| WO-2016006974-A2 | NOVEL TRIAZOLOPYRIMIDINONE OR TRIAZOLOPYRIDINONE DERIVATIVES, AND USE THEREOF | ST PHARM CO., LTD. (KR) | 2016-01-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170145016-A1 | NOVEL TRIAZOLOPYRIMIDINONE OR TRIAZOLOPYRIDINONE DERIVATIVES, AND USE THEREOF | TNKS1BP1, TNKS, TPI1 | SLC9A1 3208/4885KEAP1 897/4885BRD2 2297/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.